Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RCEL |
---|---|---|
09:32 ET | 128 | 12.93 |
09:37 ET | 100 | 12.83 |
09:42 ET | 350 | 12.77 |
09:44 ET | 500 | 12.96 |
09:55 ET | 1100 | 12.86 |
10:06 ET | 100 | 12.79 |
10:08 ET | 100 | 12.79 |
10:11 ET | 100 | 12.86 |
10:13 ET | 1400 | 12.94 |
10:15 ET | 1000 | 12.9 |
10:22 ET | 100 | 12.88 |
10:24 ET | 600 | 12.815 |
10:26 ET | 200 | 12.81 |
10:29 ET | 160 | 12.8799 |
10:31 ET | 100 | 12.79 |
10:36 ET | 100 | 12.82 |
10:44 ET | 200 | 12.79 |
10:47 ET | 100 | 12.79 |
10:51 ET | 100 | 12.8 |
10:58 ET | 593 | 12.8 |
11:03 ET | 100 | 12.8599 |
11:05 ET | 896 | 12.83 |
11:14 ET | 245 | 12.78 |
11:18 ET | 100 | 12.75 |
11:20 ET | 250 | 12.74 |
11:25 ET | 800 | 12.815 |
11:27 ET | 100 | 12.79 |
11:38 ET | 200 | 12.76 |
11:52 ET | 200 | 12.72 |
11:56 ET | 400 | 12.75 |
11:59 ET | 200 | 12.79 |
12:14 ET | 200 | 12.725 |
12:28 ET | 859 | 12.72 |
12:33 ET | 600 | 12.745 |
12:35 ET | 200 | 12.79 |
12:39 ET | 1000 | 12.73 |
12:44 ET | 600 | 12.81 |
12:46 ET | 399 | 12.87 |
12:48 ET | 100 | 12.87 |
12:50 ET | 200 | 12.87 |
12:51 ET | 510 | 12.81 |
12:55 ET | 500 | 12.8 |
12:57 ET | 200 | 12.795 |
01:00 ET | 10429 | 12.87 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
AVITA Medical Inc | 336.9M | -5.8x | --- |
Contineum Therapeutics Inc | 374.6M | -10.7x | --- |
Fate Therapeutics Inc | 361.0M | -1.9x | --- |
Artiva Biotherapeutics Inc | 306.0M | 0.0x | --- |
Zenas Biopharma Inc | 477.7M | -3.6x | --- |
Mersana Therapeutics Inc | 268.1M | -3.7x | --- |
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $336.9M |
---|---|
Revenue (TTM) | $60.0M |
Shares Outstanding | 26.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.59 |
EPS | $-2.23 |
Book Value | $1.91 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -98.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.